Refractory Pseudomonas bacteremia in a 2-year-old sterilized by bacteriophage therapy

Journal of the Pediatric Infectious Diseases Society

Volumn 7, Issue 3, 2018, Pages 253-256

  Duplessis, C ^a   Biswas, B ^a,b   Hanisch, B ^c,d   Perkins, M ^e   Henry, M ^a   Quinones, J ^a   Wolfe, D ^a   Estrella, L ^a   Hamilton, T ^a  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^e WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Bacteremia; Bacteriophage; Multidrug resistance; Pseudomonas aeruginosa; Sepsis

Indexed keywords

AZTREONAM; COLISTIN; MEROPENEM; POLYMYXIN B; TOBRAMYCIN;

ACINETOBACTER BAUMANNII; ANAPHYLAXIS; ARTICLE; BACTEREMIA; BLEEDING; CARDIOGENIC SHOCK; CASE REPORT; CHILD; CLINICAL ARTICLE; DISEASE SURVEILLANCE; ENTEROBACTER; ENTEROCOCCUS FAECIUM; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; KLEBSIELLA PNEUMONIAE; PHAGE THERAPY; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEPTIC SHOCK; STAPHYLOCOCCUS AUREUS; THORAX SURGERY; TREATMENT DURATION; WHOLE BODY IMAGING; BLOOD; FATALITY; MALE; MULTIDRUG RESISTANCE; PROCEDURES; PSEUDOMONAS INFECTION;

BACTEREMIA; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FATAL OUTCOME; HUMANS; MALE; PHAGE THERAPY; PSEUDOMONAS INFECTIONS;

EID: 85055677751     PISSN: 20487193     EISSN: 20487207     Source Type: Journal    
DOI: 10.1093/jpids/pix056     Document Type: Article

References (15)

1. Debarbieux L, Pirnay JP, Verbeken G, et al. A bacteriophage journey at the European Medicines Agency. FEMS Microbiol Lett 2016; 363:fnv225.
2. Hraiech S, Brégeon F, Rolain JM. Bacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current status. Drug Des Devel Ther 2015; 9:3653-63.
3. Parasion S, Kwiatek M, Gryko R, et al. Bacteriophages as an alternative strategy for fighting biofilm development. Pol J Microbiol 2014; 63:137-45.
4. Davies EV, Winstanley C, Fothergill JL, James CE. The role of temperate bacteriophages in bacterial infection. FEMS Microbiol Lett 2016; 363:fnw015.
5. Chanishvili N. Bacteriophages as therapeutic and prophylactic means: summary of the soviet and post soviet experiences. Curr Drug Deliv 2016; 13:309-23.
6. Kutter EM, Kuhl SJ, Abedon ST. Re-establishing a place for phage therapy in western medicine. Future Microbiol 2015; 10:685-8.
7. Schooley RT, Biswas B, Gill JJ, et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother 2017; in press.
8. Speck P, Smithyman A. Safety and efficacy of phage therapy via the intravenous route. FEMS Mirobiol Lett 2016; 363:242.
9. Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of phage therapy. Future Microbiol 2013; 8:769-83.
10. Kaźmierczak Z, Górski A, Dąbrowska K. Facing antibiotic resistance: Staphylococcus aureus phages as a medical tool. Viruses 2014; 6:2551-70.
11. Tzeng A, Tzeng TH, Vasdev S, et al. Treating periprosthetic joint infections as biofilms: key diagnosis and management strategies. Diagn Microbiol Infect Dis 2015; 81:192-200.
12. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage 2011; 1:66-85.
13. Abedon ST. Phage therapy of pulmonary infections. Bacteriophage 2015; 5:e1020260.
14. Loc-Carrillo C, Abedon ST. Pros and cons of phage therapy. Bacteriophage 2011; 1:111-4.
15. Regeimbal JM, Jacobs AC, Corey BW, et al. Personalized therapeutic cocktail of wild environmental phages rescues mice from Acinetobacter baumannii wound infections. Antimicrob Agents Chemother 2016; 60:5806-16.